Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future
- PMID: 32220406
- PMCID: PMC7293894
- DOI: 10.1016/j.jsat.2020.02.002
Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future
Abstract
Economic evaluations provide evidence that informs stakeholders on how to efficiently allocate real and financial healthcare resources. The purpose of this study was to review and discuss the integration of economic evaluations into the National Drug Abuse Treatment Clinical Trials Network (CTN) since its inception, as well as expectations for the future of this relationship. A systematic review was performed on published and planned CTN economic evaluations in the CTN dissemination library and PubMed. The well-established Drummond checklist was used to evaluate the comprehensiveness and methodological rigor of published articles. One hundred thirty-eight ancillary, follow-up, or original protocols were reviewed, and 78 potentially relevant published articles were identified. A total number of 14 protocols included an economic evaluation. Of these, 6 protocols were completed, 2 were reported as active, and 6 were reported as in-development at the time of this review. Of the 78 published articles, 9 met the inclusion criteria. As gauged by the Drummond checklist, the quality of CTN published economic evaluations were found to improve over time, and recent published articles were identified as guides to cutting-edge economic research. As the CTN continues to grow and mature, it is imperative that high-quality economic evaluations are incorporated alongside trials in order to maximize the public health impact of the CTN.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest This research was supported in part by the National Institute on Drug Abuse (P30DA040500, R01DA035808, R01DA046721, UG1DA040314, UG1DA013732, UG1DA013035, UG1DA015831, UG1DA040309). The content of this article is solely the responsibility of the authors and does not necessarily represent the official view of the funding agency or the US government.
Figures
References
-
- Alter MJ (2006). Epidemiology of viral hepatitis and HIV co-infection. J Hepatol, 44(1 Suppl), S6–9. - PubMed
-
- Balestroni G, & Bertolotti G. (2012). [EuroQol-5D (EQ-5D): an instrument for measuring quality of life]. Monaldi Arch Chest Dis, 78(3), 155–159. - PubMed
-
- Braithwaite RS, Meltzer DO, King JT Jr., Leslie D, & Roberts MS (2008). What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care, 46(4), 349–356. - PubMed
-
- Brauer CA, Neumann PJ, & Rosen AB (2007). Trends in cost effectiveness analyses in orthopaedic surgery. Clin Orthop Relat Res, 457, 42–48. - PubMed
-
- Briggs AH, & O’Brien BJ (2001). The death of cost-minimization analysis? Health Econ, 10(2), 179–184. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
